Pay in 4 interest-free payments of $13.75 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Vismodegib (GDC-0449)
48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3
(2012) Nature 485(7396):62-8
Rodriguez AL
41(7):393-403
CC-930 - CAS# 899805-25-5 Catalog No.:M6544-10 Vismodegib (GDC-0449)CC 930, also known as Tanzisertib, CAS No. 899805 25 5, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC 930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC 930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of
US$ 75.00
US$ 85.00
US$ 68.00
US$ 38.00
US$ 180.00
US$ 82.00
US$ 38.00